SecBot SecBot
8-K ·Filed Feb 24, 2026

XRAY

DENTSPLY SIRONA Inc.
NEUTRAL
Impact 3/10
Horizonmonths Processed8mo ago SEC0000818479-26-000058
8-K context-dependent: Items 5.02, 7.01
Actionable Insight • Neutral

Monitor the company's next earnings call for any commentary on the strategic direction from the newly expanded board, particularly regarding the Return-to-Growth action plan. The addition of financial experts to key committees may signal a focus on capital allocation and financial discipline.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$12.80
T+0 close · Feb 24, 2026 · via day close
Latest settled
−23.13%
T+60 · $9.84
Vs SPY
−30.08%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 25 $12.80entry
  2. T+1 · 9mo ago −0.70%α −0.16% · $12.71
  3. T+5 · 9mo ago +5.00%α +6.10% · $13.44
  4. T+20 · 8mo ago −8.75%α −3.51% · $11.68
  5. T+60 · 6mo ago −23.13%α −30.08% · $9.84
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

DENTSPLY SIRONA Inc. announced the appointment of James Forbes and Brian McKeon to its Board of Directors, effective February 27, 2026, as part of its ongoing board refreshment process. This follows the recent appointment of Don Zurbay and the retirement announcement of Willie Deese. The new directors bring extensive financial leadership and board experience to support the company's Return-to-Growth strategy.

Key Facts

  • James D. Forbes and Brian P. McKeon appointed to the Board of Directors effective February 27, 2026
  • Board size increased from 11 to 13 members
  • Willie A. Deese notified the Board of his intent not to seek re-election at the 2026 annual meeting
  • Forbes brings 30 years of healthcare investment banking experience, previously at Morgan Stanley
  • McKeon brings 25 years of public company CFO experience, previously at IDEXX Laboratories
  • Forbes will serve on the Compensation & Human Capital Committee
  • McKeon will serve on the Audit and Finance Committee and Science and Technology Committee

Financial Impact

No direct financial impact reported

compensationgovernance

Risk Factors

  • New board members may bring different strategic perspectives that could shift company direction
  • Board refreshment process could continue with additional changes

Market Snapshot

Exchange
Nasdaq

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000818479-26-000058
Exhibit: ex991bodappointments_vff.htm0000818479-26-000058
Document: 0000818479-26-000058-index-headers.html0000818479-26-000058
Document: 0000818479-26-000058-index.html0000818479-26-000058
Document: 0000818479-26-000058.txt0000818479-26-000058

US Market Status

Market Closed · Opens in 5h 59m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 24, 2026